Kudo Kenichiro, Kawakado Keita, Kawajiri Tomoka, Nishi Tatsuya, Makimoto Go, Tamura Tomoki, Kuyama Shoichi, Tanimoto Mitsune
Department of Respiratory Medicine, Iwakuni Clinical Center, Japan.
Intern Med. 2020 Jul 15;59(14):1739-1740. doi: 10.2169/internalmedicine.4449-20. Epub 2020 Apr 16.
The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutation-positive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.
达可替尼是治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）的关键药物，其对中枢神经系统的疗效尚不清楚。我们在此介绍使用达可替尼治疗一名老年患者EGFR突变阳性NSCLC的多发脑转移瘤的经验。本病例报告表明，达可替尼可能是脑转移患者的重要治疗选择。
